App-Quantinova.ai

A PHASE I HEALTHY VOLUNTEER STUDY ON THE RELATIVE BIOAVAILABILITY AND FOOD EFFECT OF CAPSULE AND GRANULE FORMULATIONS OF SELUMETINIB

Sarit Cohen-Rabbie - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Neurofibromatosis type 1

ARRY-142886

IDH1/2wt ANAPLASTIC GLIOMAS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL: OVERALL SURVIVAL RELATED TO TREATMENT, MGMT STATUS AND MOLECULAR FEATURES OF GLIOBLASTOMA

C Mircea S Tesileanu - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gliomas

N/A

EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN EXPANDED DATASET

Sbastien Perreault - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Larotrectinib

DIPG HARBOUR ALTERATIONS TARGETABLE BY MEK INHIBITORS, WITH ACQUIRED RESISTANCE MECHANISMS OVERCOME BY COMBINATORIAL INHIBITION

Elisa Izquierdo - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse intrinsic pontine glioma

Ulixertinib

LOSS OF THE H4 LYSINE METHYLTRANSFERASE KMT5B DRIVES INVASION / MIGRATION BY DEPLETING H3K27me3 AT LOCI OTHERWISE RETAINED IN H3K27M MUTANT DIPG CELLS

Ketty Kessler - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse intrinsic pontine glioma

N/A

TUMOR-IMMUNE INTERACTIONS ARE DYNAMIC AND INFLUENCE THE EVOLUTIONARY TRAJECTORY OF ADULT DIFFUSE GLIOMA

Frederick Varn - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Gliomas

N/A

EPIDEMIOLOGICAL TRENDS FOR LONGER TERM GBM SURVIVORS POST STUPP

Samantha Forner - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

COMBINATION OF EPIGENETIC ENZYME INHIBITORS, GSK-J4 AND BELINOSTAT, REVEALS HIGH EFFICACY IN IDH1 MUTANT GLIOMAS

Alisan Kayabolen - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Low-grade gliomas

5-Azacytidine

THE microRNA miR-138 MAY BE RESPONSIBLE FOR SOME OF THE EFFECTS OF METABOLIC KETOSIS ON MALIGNANT GLIOMA

Richard Perryman - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gliomas

N/A

DEVELOPMENT OF RETROVIRAL REPLICATING VECTORS ENCODING SEQUENCE-OPTIMIZED NITROREDUCTASE FOR PRODRUG ACTIVATOR GENE THERAPY IN HUMAN GLIOMA MODELS

Sara Collins - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

High-Grade Gliomas

vocimagene amiretrorepvec + Toca FC

ARTIFICIAL INTELLIGENCE-BASED IDENTIFICATION OF COMBINED VANDETANIB AND EVEROLIMUS IN THE TREATMENT OF ACVR1-MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA

Diana Carvalho - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse intrinsic pontine glioma

Everolimus

IND-ENABLING CHARACTERIZATION OF DUAL DRD2- AND ClpP-TARGETING AGENT ONC206 AS THE NEXT IMIPRIDONE FOR CLINICAL NEURO-ONCOLOGY

Varun Prabhu - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Dopamine hydrochloride

GLIOBLASTOMA IN THE OLDER PERSON – HOW DO WE DECIDE ON TREATMENT?

Cressida Lorimer - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Glioblastoma

N/A

LIFESTYLE COACHING IS FEASIBLE AND IMPROVES PILOT OUTCOMES IN FATIGUED BRAIN TUMOUR PATIENTS: THE BT-LIFE (BRAIN TUMOURS, LIFESTYLE INTERVENTIONS, AND FATIGUE EVALUATION) MULTI-CENTRE, PHASE II RCT

Alasdair G Rooney - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cerebral metastases

N/A

THE EXPERIENCE OF FATIGUED BRAIN TUMOUR PATIENTS RECEIVING INNOVATIVE LIFESTYLE INTERVENTIONS: QUALITATIVE RESULTS FROM THE BT-LIFE RANDOMISED CONTROLLED TRIAL

Claire Torrens - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cerebral metastases

N/A

SERVICE RECONFIGURATION INTO AN URGENT ELECTIVE PATHWAY FOR THE MANAGEMENT OF GLIOBLASTOMA PATIENTS IMPROVES OUTCOMES, COSTS AND PATIENT EXPERIENCE AND ADJUNCT USE: A SINGLE CENTRE SIX YEAR REVIEW

Rosa Sun - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

BT-LIFE (BRAIN TUMOURS, LIFESTYLE INTERVENTIONS, AND FATIGUE EVALUATION): LESSONS LEARNED FROM RUNNING A NOVEL MULTI-SECTORAL RESEARCH TRIAL

Alasdair G Rooney - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

INCIDENCE AND OUTCOMES OF BRAIN METASTASES IN PATIENTS WITH EXTRA-PULMONARY NEUROENDOCRINE NEOPLASMS

Zainul Abedin Kapacee - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

N/A

STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES AT THE GUY’S CANCER CENTER, LONDON: AN AUDIT FOR THE FIRST 17 MONTHS

Kallol Bhadra - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

N/A

HARMONIZING LANGUAGE TO MAXIMIZE IMPACT: AN UPDATE ON COMMON DATA ELEMENTS FOR MENINGIOMA AND REVIEW OF CLINICAL TRIALS IN MENINGIOMA

Justin Wang - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Meningiomas

N/A

Filters

45280 Abstracts